TABLE 1.
Comparison between healthy controls and JDM patients for the percentage of lymphocytes expressing CD19 (B cells), the proportion of B cells expressing the cell surface activation marker CD23, CD25, CD54, or CD69, and the proportion of non-B cells expressing CD54
| Group (n)a | % Lymphocytes expressing CD19 | % CD19+ cells expressing:
|
% Non-CD19+ CD54+ | |||
|---|---|---|---|---|---|---|
| CD23 | CD25 | CD54 | CD69 | |||
| Healthy controls (37) | 17 ± 1 (P < 0.0001)b | 81 ± 2 (NS) | 15 ± 1 (NS) | 85 ± 2 (p = .02) | 15 ± 2 (NS) | 50 ± 2 (P = 0.0002) |
| Healthy controls (<10 yr old) (12) | 19 ± 1 (P = 0.0017)c | 78 ± 3 (NS) | 16 ± 1 (NS) | 80 ± 4 (NS) | 15 ± 4 (NS) | 43 ± 4 (P = 0.013) |
| JDM patients (10) | 30 ± 3 | 83 ± 3 | 19 ± 3 | 77 ± 3 | 20 ± 4 | 25 ± 5 |
Healthy controls (n = 37) differed significantly in age from the JDM patients (11.2 ± 0.6 years [mean ± standard error of the mean] versus 5.9 ± 0.9 years, P < 0.0001) at the time of analysis. The healthy controls <10 years old did not differ significantly in age from the JDM group (7.9 ± 0.6 versus 5.9 ± 0.9, P = 0.07).
P values indicate the level of significance of the difference between the entire group of healthy children (n = 37) and the JDM patients. NS, not significant.
P values indicate the level of significance of the difference between the group of healthy children less than 10 years of age (n = 12) and the JDM patients. NS, not significant.